Anoro Ellipta 55/22mcg (umeclidinium and vilanterol) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
|
|
- Mabel Charles
- 5 years ago
- Views:
Transcription
1 Anoro Ellipta 55/22mcg (umeclidinium and vilanterol) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) Medicines Evidence Pack to Support Formulary and Guidelines Decision Making Prescribing information is provided at the back of this document
2 CONTENTS Anoro Ellipta Overview in COPD 3 Background to COPD 4 Efficacy Studies 5 Active Comparator Studies 6 Placebo Study 10 Safety 12 National Health Technology Assessment 14 Administration 15 Patient Experience 16 Adherence 16 Cost 17 Information Sources 17 References 18 Prescribing Information 20 2
3 Anoro Ellipta Overview in COPD Brand Name Generic Name Device COPD Licensed Indication BNF Class Anticipated Place in Therapy Dose Administration Anoro Ellipta 55/22mcg Umeclidinium bromide (long-acting muscarinic receptor antagonist, LAMA) and vilanterol (long-acting β 2 agonist; LABA) combination Ellipta multi-dose dry powder inhaler device Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). 3.1 Respiratory System, Bronchodilators Anoro Ellipta is a suitable treatment for symptomatic COPD patients requiring maintenance bronchodilator therapy eg. after a SABA, or those patients who are uncontrolled on their currently prescribed maintenance bronchodilator eg. step up from LAMA to combination LAMA/LABA One inhalation once daily of Anoro Ellipta 55/22mcg Inhaled via an Ellipta multi dose dry powder inhaler device Cost The 30-day cost of Anoro Ellipta is
4 Background to COPD Burden of COPD COPD is the second most common cause of emergency admission to hospital (Department of Health 2011). Even a mild grade of breathlessness is an independent marker of an increased risk of moderate-to-severe exacerbations (Mullerova et al. 2014) and patients with increased exacerbations are hospitalised more frequently (Thomas et al. 2013). Breathlessness is the most prevalent symptom of COPD and seriously impacts on a patient s quality of life. (de Oliveira et al. 2013) Breathlessness leads to a reduction in physical activity resulting in a sedentary lifestyle which further increases symptoms. (ZuWallack et al. 2007) Around 40% of patients are forced to retire early due to their symptoms. (Fletcher et al. 2011) The total cost of managing breathlessness is 4-10 times more costly than exacerbation management due to frequent GP visits. (Punekar et al. 2013) The total annual direct healthcare cost of COPD to the NHS is estimated to be over 800 million. (Department of Health 2011) Current Management Bronchodilators are central to symptom management in COPD (GOLD, 2017). The current standard of care to relieve symptoms is treatment with a single bronchodilator; long-acting muscarinic antagonist (LAMA). (NICE 2010). In the UK, COPD treatment is managed through following NICE guidelines. NICE guidelines: Management of chronic obstructive pulmonary disease in primary and secondary care can be found at Internationally, the Global initiative for Chronic Obstructive Lung Disease (GOLD) guidelines is utilised. The GOLD global strategy for diagnosis, management and prevention of COPD can be found at 4
5 Efficacy Studies The airflow classification and GOLD groups in the efficacy studies in this document are based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016 Strategy Three randomised, multicentre, double dummy, blinded, parallel group comparative efficacy studies were conducted comparing once daily Anoro Ellipta 55/22mcg (umeclidinium/ vilanterol) versus Spiriva HandiHaler 18mcg (tiotropium) in breathless (MRC 3) patients with moderate to severe COPD. These were superiority studies with the hypothesis that Anoro Ellipta would demonstrate superior efficacy over tiotropium. The placebo controlled study was a randomised, multicentre, double-blinded, parallel group comparative efficacy study conducted comparing once daily Anoro Ellipta versus placebo in patients with moderate to severe COPD. Table 2 Summary of Clinical Endpoints for Active Comparator and Placebo Controlled Trials Primary: Trough FEV 1 Active Comparator Studies Anoro Ellipta vs. tiotropium (Maleki-Yazdi MR et al 2014, Decramer et al. 2014) Secondary: 0-6hr weighted mean FEV 1 Other efficacy endpoints: Rescue medication use SGRQ, TDI* Placebo Study Anoro Ellipta vs. placebo (Donohue et al. 2013, Resp Med) Primary: Trough FEV 1 Secondary: TDI 0-6hr weighted mean FEV 1 Other efficacy endpoints: SGRQ 24 weeks 24 weeks Patient Population Clinical history of COPD in accordance with the ERS definition Post salbutamol FEV 1 / FVC ratio of 0.70 and FEV 1 70% predicted normal Dyspnoea score of 3 on the MRC Dyspnoea Scale 10 pack year smoking history Patients were excluded if they were on long term oxygen therapy or who had poorly controlled COPD leading to Hospitalisation in the previous 12 weeks Acute worsening of COPD that needed either corticosteroids, antibiotics, or required treatment prescribed by a physician in the previous 6 weeks Medical Research Council (MRC), Transition Dyspnoea Index (TDI) focal score, Quality of life measured by the St George s Respiratory Questionnaire (SGRQ) *TDI was not investigated in ZEP study (Maleki). Details of the blinding process for all tiotropium comparator studies discussed in this document can be found on page 474 in Decramer M et al. Lancet Respir Med 2014; 2:
6 Demographics and Baseline Characteristics Table 3 Patient Demographics and Baseline Characteristics ZEP (Maleki-Yazdi MR et al. 2014) Tiotropium n Anoro Ellipta 55/22mcg n = 454 DB (Maleki Yazdi MR et al. 2014; Decramer et al 2014) Tiotropium n = 203 Anoro Ellipta 55/22mcg n = 207 DB (Decramer et al 2014; Maleki Yazdi MR et al. 2014) Tiotropium n = 215 Anoro Ellipta 55/22mcg n = 217 DB (Donohue et al. 2013) Placebo n = 280 Anoro Ellipta 55/22mcg n = 413 Age (mean in years) Male (%) White (%) Predicted FEV 1 (%), Mean MRC Scale (median) Active Comparator Studies Anoro Ellipta vs. tiotropium Primary Efficacy Endpoint In three efficacy studies Anoro Ellipta improved trough FEV 1 by 112ml (p<0.001), 90ml (p<0.001), and 60ml (p=ns*) respectively compared to tiotropium. (Maleki-Yazdi MR et al. 2014, Decramer et al. 2014) (Figure 1) Figure 1 Change From Baseline in Trough FEV 1 at day LS mean change from baseline (ml) ml (p<0.001) 93ml 205ml 90ml (p<0.001) 121ml 211ml 60ml (p=ns*) 149ml 208ml 0 120% relative increase (n=905) 74% relative increase (n=410) 40% relative increase (n=432) TIO 18mcg Anoro Ellipta 55/22mcg *p=non significant due to statistical heirarchy Details of the blinding process for all tiotropium comparator studies discussed in this document can be found on page 474 in Decramer M et al. Lancet Respir Med 2014; 2:
7 Maintenance Naive Patients Anoro Ellipta showed significant improvements in trough FEV 1 vs tiotropium in IMT* and ITT* populations. There was a 2.4 times greater lung function improvement vs. tiotropium in maintenance naive patients at week 24. P<0.001, pooled post hoc data: 252ml vs. 107ml change in trough FEV 1 from baseline for Anoro Ellipta Vs. Tiotropium respectively. Individual patient-level data from studies DB , DB and ZEP were pooled and statistical re-analysis was performed. Figure 2 Change in Mean FEV 1 vs. Tio in IMT and ITT 300 Difference: 146ml (95% CI 102, 189) p<0.001 LS mean change from baseline (ml) Difference: 95ml (95% CI 71, 118) p< All patients Maintenance-naive subgroup TIO 18mcg Anoro Ellipta 55/22mcg All patients n = 1,747 (TIO n = 869; Anoro Ellipta n = 878); Maintenance-naive subgroup n = 533 (TIO n = 258; Anoro Ellipta n = 275) *IMT = Initial Maintenance Therapy; ITT = Intent to Treat Details of the blinding process for all tiotropium comparator studies discussed in this document can be found on page 474 in Decramer M et al. Lancet Respir Med 2014; 2:
8 Pooled post hoc analysis: lung function according to GOLD category and ICS use Anoro Ellipta demonstrated statistically significant improvements in trough FEV 1 vs. tiotropium at day 169 (95ml, p<0.001; CI ml) Anoro Ellipta showed statistically significant improvements vs. TIO in sub groups based on: GOLD classification (B and D: 119 and 77ml, respectively; p<0.001 for both) ICS users and non-users (70 and 121ml, respectively; p<0.001 for all subgroups) Figure 3 Mean Change from Baseline in Trough FEV 1 LS mean change from baseline (ml) *** *** *** *** *** Total GOLD B GOLD D ICS users ICS non-users Anoro Ellipta 55/22mcg TIO 18mcg ***P<0.001 Analysis based on a post hoc, pooled sub-group analysis of three 24-week, randomised, doubledummy, active-controlled, blinded, multi-centre, parallel-group studies. CI=Confidence Interval The airflow classification and GOLD groups in the efficacy studies in this document are based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016 Strategy 8
9 Secondary Efficacy Endpoint Anoro Ellipta improved weighted mean FEV 1 over 0-6 hours by 105ml (p<0.001), 74ml (p<0.005), and 96ml (p=ns*) respectively compared to tiotropium at week 24 (Maleki Yazdi MR et al. 2014; Decramer et al. 2014) *p=non significant due to statistical hierarchy Other Efficacy Endpoints Rescue Medication Use Anoro Ellipta demonstrated a reduction in rescue medication use by -0.5 (p<0.001), -0.6 (p=0.022), and -0.6 (p=ns) mean puffs/day respectively compared to tiotropium (Maleki Yazdi MR et al. 2014; Decramer et al. 2014) (Figure 4) Figure 4 Change in Mean Number of Puffs of Rescue Medication Per Day Over 24 Weeks Change in mean number of puffs/day % relative reduction (n=905) puffs/day (p<0.001) % relative reduction (n=410) puffs/day (p=0.022) % relative reduction (n=432) puffs/day (p=ns) -2.7 TIO 18mcg Anoro Ellipta 55/22mcg SGRQ Both Anoro Ellipta and tiotropium demonstrated improvements in total SGRQ score from baseline (>4 unit change). In two studies Anoro Ellipta improved SGRQ score by and units from baseline. The differences between Anoro Ellipta and tiotropium were not statistically significant (p=ns) (Decramer et al. 2014). In one study, Anoro Ellipta improved SGRQ score by units from baseline, and improved SGRQ score by 2.10 units compared to tiotropium (P=0.006) (Maleki - Yazdi MR et al. 2014) TDI Both Anoro Ellipta and tiotropium demonstrated clinically meaningful improvements in TDI focal scores of greater than 1 unit (Mahler et al. 2005) Anoro Ellipta improved TDI focal score by 2.3 units from baseline in 2 studies. Comparisons between Anoro Ellipta and tiotropium were not statistically significant (p=ns) (Decramer et al. 2014) 9
10 Placebo Study Anoro Ellipta vs. Placebo Primary Endpoints Treatment with Anoro Ellipta resulted in a 167ml improvement in the primary efficacy endpoint of trough FEV 1 versus placebo (p<0.001) at day 169. An improvement 100ml is considered clinically meaningful (Donohue et al. 2005, COPD; Donohue et al. 2013, Resp Med) (Figure 5) Figure 5 - Change from Baseline in Trough FEV 1 at Day LS mean change from baseline (ml) ml (p<0.001) 4ml 171ml Placebo (n=280) Anoro Ellipta 55/22mcg (n=413) Secondary Endpoints Anoro Ellipta demonstrated a statistical and clinically meaningful improvement in TDI focal score of 1.2 units versus placebo (p<0.001) (Donohue et al. 2013, Resp Med) Anoro Ellipta improved weighted mean FEV 1 over 0-6 hours versus placebo, an improvement of 242ml (p=ns*). (Donohue et al. 2013, Resp Med). Other Analyses Anoro Ellipta demonstrated a clinically meaningful improvement of units in SGRQ total score compared to placebo (p=ns*). (Donohue et al. 2013) Anoro Ellipta studies were specifically designed for breathless patients (MRC 3) and were not designed to evaluate the effect of treatments on COPD exacerbations. Patients were withdrawn from the study if an exacerbation occurred. *p=non significant due to statistical hierarchy 10
11 Anoro Ellipta showed a significant improvement of 112ml in FEV 1 at 15 minutes vs. Placebo Figure 6 Change from baseline in FEV 1 at 15 mins Change from baseline in FEV 1 at 15 min post dose (ml) Anoro 55/22mcg (N=413) 112ml (p<0.001) Placebo (N=280) Summary of Efficacy and Patient Reported Outcomes Table 4 Summary of Clinical Endpoints Treatment difference 1 (95% confidence intervals, p-value) Treatment comparisons with ANORO Ellipta 55/22mcg Trough FEV 1 (ml) TDI Focal Score SGRQ Total Score Use of Rescue medication 3 Anoro Ellipta (N = 413) versus Placebo (N = 280) 167 (128, 207) p< (0.7,1.7) p< (-7.88, -3.13) p=ns* -0.8 (-1.3, -0.3) p=ns* Anoro Ellipta (N = 454) versus tiotropium 18mcg (N = 451) (Maleki-Yazdi MR et al. 2014) 112 (81, 144) p<0.001 n/e (-3.61, -0.59) p= (-0.7, -0.2) p<0.001 Anoro Ellipta (N = 207) versus tiotropium 18mcg (N = 203) (Anzueto et al. 2013, Decramer et al. 2014) Anoro Ellipta (N = 217) versus tiotropium 18mcg (N = 215) (Decramer et al. 2014) 90 (39, 141) p< (10, 109) p=0.018* (-0.4, 0.5) p= (-2.12, 3.63) p= (-2.85, 2.52) p= (-1.2, -0.1) p= (-1.2, 0.0) p=0.069 N=number in Intent-to-treat population, mcg = micrograms, n/e = not evaluated 1) Least squares mean 2) Pooled data from two active comparator studies (Anzueto, 2013, Decramer,2013) 3) Difference in the mean number of puffs per day over Weeks *p=non significant due to statistical hierarchy Details of the blinding process for all tiotropium comparator studies discussed in this document can be found on page 474 in Decramer M et al. Lancet Respir Med 2014; 2:
12 Safety (Anoro Ellipta Summary of Product Characteristics 2017) The safety profile of Anoro Ellipta is based on safety experience with umeclidinium/vilanterol and the individual components from the clinical development program comprising of 6,855 patients with COPD. This includes 2,354 patients who received umeclidinium/vilanterol once daily in the phase III clinical studies, of whom 1,296 patients received the recommended dose of 55/22 micrograms in 24-week studies, 832 patients received a higher dose of 113/22 micrograms (unlicensed dose within the UK) in 24 week studies and 226 patients received 113/22 micrograms in a 12 month study. Table 6 Summary of Adverse Events Frequency of adverse event Common adverse reactions ( 1/100 to <1/10) Other important adverse reactions include: Frequency uncommon ( 1/1,000 to <1/100) Frequency rare ( 1/10,000 to <1/1,000) Adverse Event Urinary tract infection, sinusitis, nasopharyngitis, pharyngitis, upper respiratory tract infection, headache, cough, oropharyngeal pain, constipation and dry mouth. Atrial fibrillation, supraventricular tachycardia, rhythm idioventricular, tachycardia, supraventricular extrasystoles, palpitations, and hypersensitivity reactions including rash. Anaphylaxis, angioedema, and urticaria. Glaucoma, vision blurred, intraocular pressure increased and paradoxical bronchospasm. No dose adjustment for Anoro Ellipta is needed in: patients with renal impairment patients with mild or moderate hepatic impairment patients aged over 65 years (Please consult the full Summary of Product Characteristics (SmPC) for other adverse reactions) 12
13 Cardiovascular Effects Cardiovascular effects, such as cardiac arrhythmias, may be seen after the administration of muscarinic receptor antagonists and sympathomimetic agents, including umeclidinium/ vilanterol. Therefore, Anoro Ellipta should be used with caution in patients with severe cardiovascular disease. Additional Points to Note As with other inhalation therapies, administration of Anoro Ellipta may produce paradoxical bronchospasm. Treatment with Anoro Ellipta should be discontinued immediately if paradoxical bronchospasm occurs. As with other antimuscarinics Anoro Ellipta should be used with caution in patients with urinary retention or with narrow-angle glaucoma. Anoro Ellipta is for the maintenance treatment of COPD. It should not be used for the relief of acute symptoms. Acute symptoms should be treated with an inhaled short-acting bronchodilator. Anoro Ellipta should not be used in patients for the treatment of asthma. 13
14 National Health Technology Assessment National Institute for Health and Care Excellence (NICE) ( The National Institute for Health and Care Excellence (NICE) have considered Anoro for the treatment of COPD against their selection criteria for technology appraisals and have decided not to progress this beyond topic selection. Therefore Anoro will not be subject to a NICE single technology appraisal. Scottish Medicines Consortium (SMC) ( SMC advice (February 2015) for Anoro in COPD is as follows: Advice: following a re-submission. Umeclidinium/vilanterol (Anoro ) is accepted for use within NHS Scotland. Indication under review: As a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. Two randomised controlled studies demonstrated that after 24 weeks of treatment, umeclidinium/vilanterol significantly improved lung function compared with an inhaled long-acting muscarinic antagonist in patients with moderate to very severe COPD. Indirect comparisons demonstrated comparable efficacy with other combinations of long acting muscarinic antagonist plus long acting beta agonist. All Wales Medicines Strategy Group (AWMSG): ( AWMSG recommendation (February 2015) for Anoro in COPD is as follows: Umeclidinium/vilanterol (as trifenatate) (Anoro Ellipta ) is recommended as an option for use within NHS Wales as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). 14
15 Administration One inhalation of Anoro Ellipta 55/22mcg once daily for adults with COPD. Anoro Ellipta should be administered at the same time of the day, each day (morning or evening). If a dose is missed the next dose should be taken at the usual time the next day. Figure 8 - Anoro Ellipta Inhaler Open Inhale Close See SmPC or PIL for further information on inhaler technique. The Ellipta inhaler consists of two aluminium foil laminate strips of regularly distributed blisters, each containing the active drug. Every time the inhaler cover is opened one dose of medicine is prepared. The Ellipta inhaler has a dose counter which shows how many doses of medicine are left in the inhaler. Before the inhaler has been used, it shows exactly 30 doses It counts down by 1 each time the cover is opened When fewer than 10 doses are left, half of the dose counter shows red After the last dose has been inhaled, the counter shows 0 Anoro Ellipta has a 2 year shelf life. Do not store above 30 C. If stored in a refrigerator allow the inhaler to return to room temperature for at least an hour before use. Keep the inhaler inside the sealed tray to protect from moisture and only remove immediately before first use. To be used within 6 weeks of first opening of the tray. Write the date the inhaler should be discarded on the label in the space provided. The date should be added as soon as the inhaler has been removed from the tray. 15
16 Patient Experience Ease of use of the Ellipta inhaler in COPD patients has been tested. Following initial instruction on how to use the inhaler in two such studies, 98% (n=618) of COPD patients used the Ellipta inhaler correctly at day one. Correct inhaler use was re-assessed after 6 weeks of treatment using the demonstration inhaler, without further verbal instruction or demonstration to the patient; 99% (n=580) of subjects still used their Ellipta inhaler correctly. After 6 weeks of treatment, ease of use was assessed and 98-99% of patients found their Ellipta inhaler easy or very easy to use (Riley et al. 2013). In 2 six month studies (n=1020) 63% patients preferred the Ellipta inhaler to the HandiHaler device on the basis of time to use and the number of steps required. (Riley et al. 2013) COPD patients across a range of severities were able to generate a peak inspiratory flow rate (PIFR) of greater than 43 L/min through the Ellipta device (Prime et al. 2012). The inhalation profiles generated by a range of COPD patients (42-129ml/min) were then replicated using an electronic lung (GSK) breathing simulator. In vitro, drug delivery to the electronic lung was consistent across the full range of PIFRs, ml/min. (Hamilton et al. 2012) Adherence Once daily treatment has the potential to improve adherence and simplify treatment in chronic diseases such as COPD, however there is no current data to directly support increased adherence with Anoro Ellipta compared to other (LAMA/LABA combinations in COPD). There is some evidence in the LAMA class that a once daily COPD inhaler therapy may improve compliance. In a retrospective analysis of 50,076 patients in the US, looking specifically at adherence, COPD patients who were initiated on treatment with once-daily dosing (tiotropium; n=3,678) had significantly higher adherence over 12 months than patients initiated on treatments which were dosed twice a day (e.g. Seretide [fluticasone propionate/ salmeterol] and Symbicort; n=25,011); (43.3% vs 37.0%, p<0.0001). (Toy et al. 2011) Patient preference is an important factor when choosing an inhaler device for COPD. in a recently published retrospective observational study of 2138 patients, 44.7% preferred a once daily schedule. (Price et al. 2013) 16
17 Cost The 30-day cost of Anoro Ellipta 55/22mcg is Data to calculate the budget impact of Anoro Ellipta, specific to a locality, can be provided by your local GSK account manager and health outcomes specialists if required. Information sources Should you require further medical information on Anoro Ellipta please contact the GSK medical information team via our customer contact centre: By phone on Lines are open from Monday-Friday 8am 6pm. Outside these hours and on bank holidays, an answer phone service is available. By at customercontactuk@gsk.com Your local GSK account team of therapy, medical and health outcomes specialists will also be able to support you if required. 17
18 References Anoro Ellipta SmPC de Oliveira, J. Clinical significance in COPD patients followed in a real practice. Multidiscip. Respir.Med., 8, (1) 43 available from: PM: , Decramer, M. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomized controlled trials. Lancet Resir Med, 2, (6) Department of Health. Consultation on a strategy for services for chronic obstructive pulmonary disease (COPD) in England Department of Health. An outcomes strategy for people with chronic obstructive pulmonary disease (COPD) and asthma in England Donohue, J. Minimal clinically important differences in COPD lung function. COPD., 2, (1) available from: PM: Donohue, J. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25mcg in COPD. Respir.Med., 107, (10) available from: PM: Fletcher, M. COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC. Public Health, 11, 612 available from: PM: Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Available from: Hamilton, M. Ex-Vivo Product Performance of Fluticasone Furoate/vilanterol Delivered from a Novel Dry Powder Inhaler, Using the Electronic Lung to Replicate Asthma and COPD Patient Inhalation Profiles. Am J Respir Crit Care Med 185, A Mahler, D. The MCID of the transition dyspnea index is a total score of one unit. COPD., 2, (1) available from: PM: Maleki-Yazdi MR. Efficacy and safety of uneclidinium/vilanterol 62.5/25mcg and tiotropium 18mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med., 108 (12), / Mullerova, H. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS.One., 9, (1) e85540 available from: PM: NICE. Chronic Obstructive Pulmonary Disease, Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care (partial update) Continues on next page 18
19 References Price, D. Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study. Prim.Care Respir.J., 22, (2) available from: PM: Prime D. Comparison Of Inhalation Profiles Through A Novel Dry Powder Inhaler (ndpi) and Lung Function Measurements for Healthy Subjects, Asthma and Chronic Obstructive Pulmonary Disease (COPD) Patients. Am J Respir Crit Care Med 185, A Punekar, Y. COPD management costs among newly diagnosed COPD patients in the UK primary care setting. Am J Respir Crit Care Med, A Riley, J. Use of a new dry powder inhaler to deliver umeclidinium/vilanterol in the treatment of COPD. Eur Respir J. 42, 880s Thomas, M. No room to breathe: the importance of lung hyperinflation in COPD. Prim.Care Respir.J., 22, (1) available from: PM: Toy, E. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir.Med., 105, (3) available from: PM: ZuWallack, R. How are you doing? What are you doing? Differing perspectives in the assessment of individuals with COPD. COPD., 4, (3) available from: PM: , (last accessed January 2017) (last accessed January 2017) (last accessed January 2017) 19
20 Anoro Ellipta (umeclidinium bromide/vilanterol [as trifenatate]) Prescribing information (Please consult the full Summary of Product Characteristics (SmPC) before prescribing) Anoro Ellipta (umeclidinium bromide/vilanterol [as trifenatate]) Prescribing information (Please consult the full Summary of Product Characteristics (SmPC) before prescribing) Anoro 55/22mcg (umeclidinium bromide/vilanterol [as trifenatate]) inhalation powder. Each single inhalation provides a delivered dose (the dose leaving the mouthpiece) of 55 micrograms umeclidinium (equivalent to 65 micrograms of umeclidinium bromide) and 22 micrograms of vilanterol (as trifenatate). Indications: Anoro is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Dosage and administration: Inhalation only. One inhalation once daily of Anoro. Contraindications: Hypersensitivity to the active substances or to any of the excipients (lactose monohydrate and magnesium stearate). Precautions: Anoro should not be used in patients with asthma. Treatment with Anoro should be discontinued in the event of paradoxical bronchospasm and alternative therapy initiated if necessary. Cardiovascular effects may be seen after the administration of muscarinic receptor antagonists and sympathomimetics therefore Anoro should be used with caution in patients with severe cardiovascular disease. Anoro should be used with caution in patients with urinary retention, narrow angle glaucoma, convulsive disorders, thyrotoxicosis, hypokalaemia, hyperglycaemia and severe hepatic impairment. No dosage adjustment is required in renal or mild to moderate hepatic impairment. Acute symptoms: Anoro is not indicated for acute episodes of bronchospasm. Warn patients to seek medical advice if short-acting inhaled bronchodilator use increases, a re-evaluation of the patient and of the COPD treatment regimen should be undertaken. Interactions with other medicinal products: Avoid ß-blockers. Caution is advised when co-administering with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, itraconazole, ritonavir, telithromycin). Anoro should not be used in conjunction with other long-acting ß 2 -adrenergic agonists or medicinal products containing long-acting muscarinic antagonists. Caution is advised with concomitant use with methylxanthine derivatives, steroids or non-potassium-sparing diuretics as it may potentiate possible hypokalaemic effect of ß 2 -adrenergic agonists. Fertility, pregnancy, and breast-feeding: No available data. Balance risks against benefits. Side effects: Common ( 1/100 to <1/10): urinary tract infection, sinusitis, nasopharyngitis, pharyngitis, upper respiratory tract infection, headache, cough, oropharyngeal pain, constipation and dry mouth. Other important side effects include: Uncommon ( 1/1,000 to <1/100) atrial fibrillation, supraventricular tachycardia, rhythm idioventricular, tachycardia, supraventricular extrasystoles, palpitations, and hypersensitivity reactions including rash. Rare ( 1/10,000 to <1/1,000) anaphylaxis, angioedema, and urticaria. Glaucoma, vision blurred, intraocular pressure increased and paradoxical bronchospasm. See SmPC for other adverse reactions. Legal category: POM. Presentation and Basic NHS cost: Anoro Ellipta. 1 inhaler x 30 doses. Anoro Ellipta 55/22mcg Marketing authorisation (MA) no. 55/22mcg 1x30 doses [EU/1/14/898/002]; MA holder: Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK. Last date of revision: Jan UK/UCV/0095/15(2). Anoro and Ellipta are registered trademarks of the GlaxoSmithKline group of companies. All rights reserved. Anoro was developed in collaboration with Innoviva Inc. Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to GlaxoSmithKline on ANORO ELLIPTA was developed in collaboration with 2017 GSK group of companies. All Rights Reserved.
InforMing the PAthway of COPD Treatment 1
InforMing the PAthway of COPD Treatment 1 A landmark trial in over 10,000 symptomatic COPD patients who had experienced at least one exacerbation in the last 12 months 1 (fluticasone furoate/umeclidinium/vilanterol)
More informationThe only COPD Triple Therapy delivered in a single daily inhalation. 1 Improvement in quality of life vs. ICS/LABA. 2
The only COPD Triple Therapy delivered in a single daily inhalation. 1 Improvement in quality of life vs. ICS/LABA. 2 Trelegy Ellipta is indicated for maintenance treatment in adult patients with moderate-to-severe
More informationWhat is the current cost of COPD (Chronic Obstructive Pulmonary Disease) therapies?
What is the current cost of COPD (Chronic Obstructive Pulmonary Disease) therapies? Medicines in the COPD Ellipta portfolio are highlighted in orange on the graph below: Incruse Ellipta (umeclidinium)
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationCase Study Simplifying and streamlining COPD treatment
Case Study Simplifying and streamlining COPD treatment The production of this case study has been organised and sponsored by GlaxoSmithKline. The healthcare professional involved received no payment for
More informationRelvar Ellipta (fluticasone furoate and vilanterol as trifenatate) for the treatment of patients with COPD
Relvar Ellipta (fluticasone furoate and vilanterol as trifenatate) for the treatment of patients with COPD Medicines evidence pack to support formulary and guidelines decision making Prescribing information
More informationIncruse Ellipta 55mcg (umeclidinium bromide) for the relief of symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD):
Incruse Ellipta 55mcg (umeclidinium bromide) for the relief of symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD): An introduction for Clinical Commisioning Groups and Health
More informationumeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline
umeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline 04 July 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationEvidence Summary to support COPD formulary decision making and guideline development
Evidence Summary to support COPD formulary decision making and guideline development Prescribing and adverse event reporting information can be found on the final pages of this document. Anoro, and Ellipta
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationglycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.
glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed
More informationBudgetary Implications of Introducing the GSK Ellipta Portfolio for COPD in the UK
Budgetary Implications of Introducing the GSK Ellipta Portfolio for COPD in the UK Poster No. PRS20 Harding T 1, Thompson G 1, Mulley P 2 1 Health Outcomes, UK Pharma, GlaxoSmithKline, Stockley Park, UK
More informationA comparison of once-daily triple therapy with once-daily dual therapy in the treatment of symptomatic COPD
A comparison of once-daily triple therapy with once-daily dual therapy in the treatment of symptomatic COPD The IMPACT trial EVIDENCE UPDATE This Guidelines supplement has been commissioned by GlaxoSmithKline.
More informationEvidence Summary to support COPD formulary decision making and guideline development
Evidence Summary to support COPD formulary decision making and guideline development Prescribing and adverse event reporting information can be found on the final page of this document. Trelegy and Ellipta
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationThis supplement has been developed in partnership with GlaxoSmithKline. Evidence Update
This supplement has been developed in partnership with GlaxoSmithKline cpd credits Evidence Update Respiratory A comparison of once-daily triple therapy with once-daily dual therapy in the treatment of
More informationNot available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP FLUTICASONE FUROATE/VILANTEROL COMBINATION INHALER - ASTHMA Policy agreed by Vale of York CCG (date) Drug, Treatment, Device name Fluticasone
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationUtibron Neohaler. (indacaterol, glycopyrrolate) New Product Slideshow
Utibron Neohaler (indacaterol, glycopyrrolate) New Product Slideshow Introduction Brand name: Utibron Neohaler Generic name: Indacaterol, glycopyrrolate Pharmacological class: Long-acting beta2- agonist
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationSummary of the risk management plan (RMP) for Laventair (umeclidinium bromide and vilanterol)
EMA/258177/2014 Summary of the risk management plan (RMP) for Laventair (umeclidinium bromide and vilanterol) This is a summary of the risk management plan (RMP) for Laventair, which details the measures
More informationA COPD medication delivery device option: an overview of the NEOHALER
A COPD medication delivery device option: an overview of the NEOHALER 2017 Sunovion Pharmaceuticals Inc. All rights reserved 9/17 RESP019-17 Indication and Boxed Warning INDICATION ARCAPTA NEOHALER (indacaterol)
More informationSummary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate)
EMA/605453/2014 Summary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate) This is a summary of the risk management plan (RMP) for Duaklir Genuair, which
More informationEvidence Review for Prescribing Clinical Network
Summary page Evidence Review for Prescribing Clinical Network Treatment: LABA/LAMA Combination devices in COPD Anoro Ellipta, Ultibro and Duaklir Genuair Prepared by: Noreen Devanney Topic Submitted by:
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More informationsummarising clinical guidelines for primary care Chronic obstructive pulmonary disease in over 16s: diagnosis and management
summarising clinical guidelines for primary care Chronic obstructive pulmonary disease in over 16s: diagnosis and management National Institute for Health and Care Excellence PREPRINT cpd credits The production
More informationINCRUSE ELLIPTA PRODUCT INFORMATION
INCRUSE ELLIPTA PRODUCT INFORMATION NAME OF THE MEDICINE Umeclidinium (as bromide) Structure of umeclidinium bromide: OH N O Br Chemical Name: The chemical name of umeclidinium bromide is 1- Azoniabicyclo[2.2.2]octane,
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationroflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd
roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd 06 August 2010 (Issued 10 September 2010) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE December 2014 Review Date: December 2017 Bulletin 206 : DuoResp Spiromax 160 / 4.5 and 320 / 9 budesonide & formoterol dry powder inhaler JPC Recommendations
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationRelvar Ellipta (fluticasone furoate/vilanterol [as trifenatate]) for the treatment of patients with asthma
Relvar Ellipta (fluticasone furoate/vilanterol [as trifenatate]) for the treatment of patients with asthma Evidence Summary to support formulary decision making and guideline development Prescribing and
More informationNew Medicines Committee Briefing July Glycopyrronium bromide/indacaterol (Ultibro ) for maintenance treatment of adults with stable COPD
Ultibro is to be reviewed for use within: New Medicines Committee Briefing July 2017 Glycopyrronium bromide/indacaterol (Ultibro ) for maintenance treatment of adults with stable COPD Summary: Primary
More informationfluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK
fluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK 09 May 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationAdjunct Associate Professor Robert Young
Adjunct Associate Professor Robert Young General Physician Auckland City Hospital 7:00-7:55 GlaxoSmithKline Breakfast Session - COPD New approaches in the management of COPD Dr Robert Young BMedSc MBChB
More informationNEW ZEALAND DATA SHEET SEREVENT Accuhaler
NEW ZEALAND DATA SHEET SEREVENT Accuhaler Salmeterol xinafoate (50 mcg per inhalation) Presentation SEREVENT Accuhaler is a moulded plastic device containing a foil strip with 60 regularly placed blisters
More informationAWMSG SECRETARIAT ASSESSMENT REPORT. Aclidinium bromide (Eklira Genuair ) 322 micrograms inhalation powder. Reference number: 938 FULL SUBMISSION
AWMSG SECRETARIAT ASSESSMENT REPORT Aclidinium bromide (Eklira Genuair ) 322 micrograms inhalation powder Reference number: 938 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics
More informationANORO ELLIPTA PRODUCT INFORMATION. umeclidinium (as bromide)/vilanterol (as trifenatate)
ANORO ELLIPTA PRODUCT INFORMATION NAME OF THE MEDICINE umeclidinium (as bromide)/vilanterol (as trifenatate) Structure of umeclidinium bromide: OH N O Br Structure of vilanterol trifenatate: HO OH H N
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCOPD Respiratory Antimuscarinics Drug Class Monograph
Line of Business: Medi-Cal Effective Date: May 17, 2017 Revision Date: May 17, 2017 COPD Respiratory Antimuscarinics Drug Class Monograph This policy has been developed through review of medical literature,
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More information7.2 Part VI.2 Elements for a Public Summary
7.2 Part VI.2 Elements for a Public Summary 7.2.1 Part VI.2.1 Overview of disease epidemiology Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation that is usually
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationPRODUCT MONOGRAPH ANORO ELLIPTA. umeclidinium (as bromide) and vilanterol (as trifenatate) dry powder for oral inhalation
PRODUCT MONOGRAPH Pr ANORO ELLIPTA umeclidinium (as bromide) and vilanterol (as trifenatate) dry powder for oral inhalation 62.5 mcg umeclidinium and 25 mcg vilanterol per oral inhalation Inhaled Bronchodilator
More informationMEDICATION GUIDE ANORO ELLIPTA
MEDICATION GUIDE ANORO ELLIPTA [a-nor oh e-lip-ta] (umeclidinium and vilanterol inhalation powder) for oral inhalation What is the most important information I should know about ANORO ELLIPTA? ANORO ELLIPTA
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr ANORO ELLIPTA umeclidinium (as bromide) and vilanterol (as trifenatate) dry powder for oral inhalation This leaflet is part III of a three-part "Product Monograph" published
More informationPharmacist Objectives. Pulmonary Update. Outline. Technician Objectives. GOLD Guidelines. COPD Diagnosis 9/22/2017
Pharmacist Objectives Pulmonary Update Patty Marshik, PharmD Associate Professor University of New Mexico College of Pharmacy pmarshik@salud.unm.edu Discuss the new Global Initiative for Chronic Obstructive
More informationPatient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationIndication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationANORO ELLIPTA (Umeclidinium Bromide/Vilanterol Inhalation Powder) For Treatment of Chronic Obstructive Pulmonary Disease NDA
GlaxoSmithKline Inc. 5 Moore Drive Research Triangle Park, NC 27709 ANORO ELLIPTA (Umeclidinium Bromide/Vilanterol Inhalation Powder) For Treatment of Chronic Obstructive Pulmonary Disease NDA 203975 FDA
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE Bulletin 218: September 2015 Review Date: September 2018 LAMA / LABA combination inhalers in COPD- Place in therapy review and choice of therapy JPC Recommendations:
More informationNEW ZEALAND DATA SHEET SERETIDE Accuhaler
NEW ZEALAND DATA SHEET SERETIDE Accuhaler Salmeterol xinafoate 50 mcg and Fluticasone (100 mcg, 250 mcg or 500 mcg) Presentation SERETIDE Accuhaler 50 mcg/100 mcg Moulded plastic device containing a foil
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION (FLUTICASONE FUROATE/VILANTEROL) (Breo Ellipta GlaxoSmithKline) Indication: Chronic Obstructive Pulmonary Disease Recommendation: The Canadian Drug Expert Committee (CDEC) recommends
More informationSummary of the risk management plan (RMP) for DuoResp Spiromax (budesonide / formoterol)
EMA/126654/2014 Summary of the risk management plan (RMP) for DuoResp Spiromax (budesonide / formoterol) This is a summary of the risk management plan (RMP) for DuoResp Spiromax, which details the measures
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr ANORO ELLIPTA umeclidinium (as bromide) and vilanterol (as trifenatate) dry powder for oral inhalation This leaflet is part III of a three-part "Product Monograph" published
More informationRe-Submission. roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd. Published 11 September
Re-Submission roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd 4 August 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr ANORO ELLIPTA umeclidinium (as bromide) and vilanterol (as trifenatate) dry powder for oral inhalation This leaflet is part III of a three-part "Product Monograph" published
More information14 41 minutes Vd 218 t ½ 22 to 70 Clearance hours Protein Binding 71%, active metabolite 42% Bioavailability 3%
Brand Name: Yupelri Generic Name: revefenacin Manufacturer: Mylan Drug Class: Anticholinergic Uses: Labeled Uses: inhalation solution for maintenance treatment of COPD 1 Unlabeled Uses: no off-label indications
More informationRevefenacin (TD-4208) Phase 3 Efficacy Results
Revefenacin (TD-4208) Phase 3 Efficacy Results Once-daily, Nebulized Long-Acting Muscarinic Antagonist (LAMA) October 20, 2016 THERAVANCE, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE are registered
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INCRUSE ELLIPTA safely and effectively. See full prescribing information for INCRUSE ELLIPTA. INCRUSE
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE September 2015 Review Date: September 2018 Bulletin 219: Choice of Long Acting Muscarinic Agent (LAMA) inhaler for COPD JPC Recommendation: The availability
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 HIROBRIZ BREEZHALER 150 micrograms, inhalation powder, hard capsules B/10 with inhaler (CIP code:
More informationAWMSG SECRETARIAT ASSESSMENT REPORT. Glycopyrronium bromide (Seebri Breezhaler ) 44 micrograms inhalation powder as hard capsules
AWMSG SECRETARIAT ASSESSMENT REPORT Glycopyrronium bromide (Seebri Breezhaler ) 44 micrograms inhalation powder as hard capsules Reference number: 1455 FULL SUBMISSION This report has been prepared by
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationInitial U.S. Approval: 2013
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BREO ELLIPTA safely and effectively. See full prescribing information for BREO ELLIPTA. BREO ELLIPTA
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory. RELVAR ELLIPTA 100 mcg/25 mcg
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory RELVAR ELLIPTA 100 mcg/25 mcg Fluticasone Furoate and Vilanterol Powder for Inhalation QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET NAME OF MEDICINE OXIS TURBUHALER Eformoterol fumarate dihydrate (6 µg per inhalation) PRESENTATION OXIS TURBUHALER is a multidose, inspiratory flow driven, metered dose, dry powder
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationSummary of the risk management plan (RMP) for Budesonide/Formoterol Teva (budesonide / formoterol)
EMA/639304/2014 Summary of the risk management plan (RMP) for Budesonide/Formoterol Teva (budesonide / formoterol) This is a summary of the risk management plan (RMP) for Budesonide/Formoterol Teva, which
More informationChronic obstructive pulmonary disease (COPD) is characterized
DANIEL E. HILLEMAN, PharmD ABSTRACT OBJECTIVE: To review the role of long-acting bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD), including the importance of treatment
More informationInhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years & over
Manufacturer Submission To The National Institute for Health and Clinical Excellence By GlaxoSmithKline UK Inhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years
More informationScottish Medicines Consortium
Scottish Medicines Consortium budesonide/formoterol 100/6, 200/6 turbohaler (Symbicort SMART ) No. (362/07) Astra Zeneca UK Limited 9 March 2007 (Issued May 2007) The Scottish Medicines Consortium (SMC)
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSummary of the risk management plan (RMP) for Vylaer Spiromax (budesonide / formoterol)
EMA/675937/2014 Summary of the risk management plan (RMP) for Vylaer Spiromax (budesonide / formoterol) This is a summary of the risk management plan (RMP) for Vylaer Spiromax, which details the measures
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationAUSTRALIAN PRODUCT INFORMATION. BREO ELLIPTA (fluticasone furoate/vilanterol trifenatate) powder for inhalation
AUSTRALIAN PRODUCT INFORMATION BREO ELLIPTA (fluticasone furoate/vilanterol trifenatate) powder for inhalation 1 NAME OF THE MEDICINE Fluticasone furoate/vilanterol trifenatate 2 QUALITATIVE AND QUANTITATIVE
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: 12/2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BREO ELLIPTA safely and effectively. See full prescribing information for BREO ELLIPTA. BREO ELLIPTA
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More informationANORO ELLIPTA (umeclidinium and vilanterol inhalation powder), for oral inhalation Initial U.S. Approval: 2013
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ANORO ELLIPTA safely and effectively. See full prescribing information for ANORO ELLIPTA. ANORO ELLIPTA
More informationAddress Comorbidities
Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure
More informationSABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA
COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationUMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationPosition within the Organisation
ASTHMA TREATMENT GUIDELINES Document Description Document Type Service Application Guidelines All healthcare professionals(hcps) caring for patients with asthma Version 4.0 Ratification date September
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationDrug Monograph. Brand Name: Arcapta Neohaler. Generic Name: Indacaterol. Manufacturer¹,²: Novartis
Drug Monograph Brand Name: Arcapta Neohaler Generic Name: Indacaterol Manufacturer¹,²: Novartis Drug Class¹,²,³, : Beta2-Adrenergic Agonist, Long-Acting Uses: Labeled Uses¹,²,³, : Used for long-term maintenance
More informationPRODUCT MONOGRAPH. umeclidinium (as bromide) dry powder for oral inhalation mcg umeclidinium per oral inhalation. Inhaled Bronchodilator
PRODUCT MONOGRAPH Pr INCRUSE ELLIPTA umeclidinium (as bromide) dry powder for oral inhalation 62.5 mcg umeclidinium per oral inhalation Inhaled Bronchodilator Long-Acting Muscarinic Antagonist (LAMA) GlaxoSmithKline
More information